◀ Back to BCL2

BCL2 — PCNA

Text-mined interactions from Literome

Mazumder et al., Mol Cell Biol 2002 : The p18-cyclin E expression was prevented by Bcl-2 overexpression and by the general caspase and specific caspase 3 pharmacologic inhibitors zVAD-fluoromethyl ketone ( zVAD-fmk ) and N-acetyl-Asp-Glu-Val-Asp-aldehyde ( DEVD-CHO ), indicating that it was linked to apoptosis
Kostopoulos et al., Virchows Arch 2006 (Leukemia, Lymphocytic, Chronic, B-Cell...) : The Cyclin D1 gene translocation was detected by fluorescence in situ hybridisation ( FISH ), whereas c-myc and Bcl2 genes translocation were absent
Wang et al., J Asian Nat Prod Res 2009 : 1 in high concentrations induced Bax, caspase-3, and cyclin dependent kinase (CDK) inhibitor P21 expression, whereas the expressions of cyclin CDK2, Bcl-2 , and proliferating cell nuclear antigen ( PCNA ) were decreased by 1 treatment
Brinkkoetter et al., J Clin Invest 2009 (Glomerulonephritis) : Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells
Veliz et al., Cancer Control 2012 (Leukemia, Lymphocytic, Chronic, B-Cell...) : These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab, cyclin dependent kinase inhibitors, small modular immunopharmaceuticals, Bcl-2 inhibitors , and histone deacetylase inhibitors
Xu et al., PloS one 2013 : Reduced hepatic damage was confirmed with histopathology in the sTNFR : IgG-Fc treated group, which is consistent with reduced Bcl-2 and Bax, at mRNA and protein levels, but increased hepatocyte proliferation ( PCNA )
Wada et al., Pancreas 1997 : Immunohistochemical study showed that PCNA expression appeared in the ductules and centroacinar cells from early stages after duct ligation and that Bcl-2 expression in duct cells, which was faint in normal pancreas, increased significantly when acinar cells were diminishing